Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants. \>/= 18 years of age
Histologically confirmed metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective; participants whose tumors exhibit areas of "other histology" may be enrolled, provided the tumor histology remains predominantly papillary
Prior therapy excluding (Cohort 1, TKI Naive) or including (Cohort 2, TKI Experienced) TKI
Clinically relevant disease progression according to RECIST criteria within the prior 14 months
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate hematological, renal and liver function
You may not be if
Histological diagnosis other than papillary PTC, including squamous cell variants of PTC or PTC with areas of squamous metaplasia
Active or untreated central nervous system metastases
History of or known carcinomatous meningitis
Anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study
Active squamous cell skin cancer that has not been excised or adequately healed post excision
Previous treatment with any agent that specifically and selectively targets the MEK or BRAF pathway
Prior radiotherapy to the only measurable lesion
Clinically relevant cardio-vascular disease or event within the prior 6 months
Clareo Health | A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
